FY2025 EPS Estimates for Neogen Decreased by Zacks Research

Neogen Co. (NASDAQ:NEOG - Free Report) - Zacks Research lowered their FY2025 earnings estimates for Neogen in a report issued on Tuesday, January 28th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.39 per share for the year, down from their previous estimate of $0.45. The consensus estimate for Neogen's current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen's Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.13 EPS, Q1 2027 earnings at $0.13 EPS, Q2 2027 earnings at $0.15 EPS and FY2027 earnings at $0.58 EPS.

Neogen (NASDAQ:NEOG - Get Free Report) last issued its earnings results on Friday, January 10th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.12. The firm had revenue of $231.30 million for the quarter, compared to analysts' expectations of $227.16 million. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The business's revenue was up .7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.11 earnings per share.

A number of other research analysts also recently commented on NEOG. Piper Sandler reaffirmed a "neutral" rating and issued a $13.00 price target (down previously from $16.50) on shares of Neogen in a report on Tuesday, January 21st. Guggenheim started coverage on Neogen in a research report on Thursday, December 19th. They issued a "buy" rating and a $15.00 price target for the company.

Neogen Price Performance

Shares of NASDAQ NEOG traded down $0.30 during midday trading on Friday, reaching $10.65. 1,898,724 shares of the stock traded hands, compared to its average volume of 2,969,729. The company's 50 day moving average is $12.36 and its 200 day moving average is $14.59. Neogen has a one year low of $10.60 and a one year high of $18.58. The stock has a market capitalization of $2.31 billion, a PE ratio of -4.86 and a beta of 1.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.77 and a quick ratio of 2.46.

Hedge Funds Weigh In On Neogen

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC lifted its holdings in Neogen by 142.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company's stock worth $33,000 after buying an additional 1,165 shares during the period. Blue Trust Inc. lifted its stake in shares of Neogen by 196.7% during the 4th quarter. Blue Trust Inc. now owns 3,368 shares of the company's stock worth $41,000 after purchasing an additional 2,233 shares during the last quarter. Neo Ivy Capital Management bought a new stake in Neogen during the third quarter valued at about $66,000. KBC Group NV raised its holdings in Neogen by 39.1% in the fourth quarter. KBC Group NV now owns 8,464 shares of the company's stock worth $103,000 after purchasing an additional 2,379 shares in the last quarter. Finally, Hardy Reed LLC purchased a new stake in shares of Neogen during the fourth quarter valued at about $133,000. 96.73% of the stock is currently owned by institutional investors.

Insider Transactions at Neogen

In other news, CEO John Edward Adent purchased 23,035 shares of the business's stock in a transaction dated Thursday, January 16th. The shares were purchased at an average price of $11.03 per share, for a total transaction of $254,076.05. Following the completion of the purchase, the chief executive officer now owns 269,164 shares in the company, valued at approximately $2,968,878.92. This represents a 9.36 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO David H. Naemura acquired 14,800 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was acquired at an average cost of $11.11 per share, with a total value of $164,428.00. Following the completion of the purchase, the chief financial officer now owns 61,434 shares of the company's stock, valued at $682,531.74. This trade represents a 31.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.13% of the company's stock.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.